Skip to main content
Erschienen in: Pathology & Oncology Research 4/2018

19.03.2018 | Review

Epigenetic Mechanisms and Events in Gastric Cancer-Emerging Novel Biomarkers

verfasst von: Puneet, Hasan Raza Kazmi, Soni Kumari, Satendra Tiwari, A. Khanna, Gopeshwar Narayan

Erschienen in: Pathology & Oncology Research | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Gastric cancer is one of the most common malignancy worldwide. The various genetic and epigenetic events have been found to be associated with its carcinogenesis. The epigenetic is a heritable and transient/reversible change in the gene expression that is not accompanied by modification in the DNA sequence. This event is characterized by the alteration in the promoter CpG island of the gene or histone modification. These events are associated with silencing of critical tumor suppressor gene and activation of oncogenes leading to carcinogenesis. The DNA methylation is a chemical change in the DNA sequence that most commonly occurs at cytosine moiety of CpG dinucleotide and histone, primarily on N- terminal tail that ultimately effect the interaction of DNA with chromatin modifying protein.
Hypermethylation of tumor suppressor genes and global hypomethylation of oncogenes are widely studied epigenetic modifications. There are large number of publish reports regarding epigenetic events involving gastric cancer. These changes are potentially useful in identifying markers for early diagnosis and management of this lethal malignancy. Also, role of specific miRNAs and long non coding RNAs in regulation of gene expression is gaining interest and is a matter of further investigation. In this review, we aimed to summarize major epigenetic events (DNA methylation) in gastric cancer along with alteration in miRNAs and long non coding RNAs which plays an important role in pathology of this poorly understood malignancy.
Literatur
2.
Zurück zum Zitat Tahara E (2004) Genetic pathways of two types of gastric cancer. IARC Sci Publ 157:327–349 Tahara E (2004) Genetic pathways of two types of gastric cancer. IARC Sci Publ 157:327–349
3.
4.
Zurück zum Zitat Park WS, Oh RR, Park JY, Lee SH, Shin MS, Kim YS, Kim SY, Lee HK, Kim PJ, Oh ST, Yoo NJ, Lee JY (1999) Frequent somatic mutations of the beta-catenin gene in intestinal type gastric cancer. Cancer Res 59(17):4257–4260PubMed Park WS, Oh RR, Park JY, Lee SH, Shin MS, Kim YS, Kim SY, Lee HK, Kim PJ, Oh ST, Yoo NJ, Lee JY (1999) Frequent somatic mutations of the beta-catenin gene in intestinal type gastric cancer. Cancer Res 59(17):4257–4260PubMed
5.
Zurück zum Zitat Lee TL, Leung WK, Chan MW, Ng EK, Tong JH, Lo KW, Chung SC, Sung JJ, To KF (2002) Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res 8(6):1761–1766PubMed Lee TL, Leung WK, Chan MW, Ng EK, Tong JH, Lo KW, Chung SC, Sung JJ, To KF (2002) Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res 8(6):1761–1766PubMed
6.
Zurück zum Zitat Maesawa C, Tamura G, Suzuki Y, Ogasawara S, Sakata K, Kashiwaba M, Satodate R (1995) The sequential accumulation of genetic alterations characteristic of the colorectal adenoma carcinoma sequence does not occur between gastric adenoma and adenocarcinoma. J Pathol 176(3):249–258PubMedCrossRef Maesawa C, Tamura G, Suzuki Y, Ogasawara S, Sakata K, Kashiwaba M, Satodate R (1995) The sequential accumulation of genetic alterations characteristic of the colorectal adenoma carcinoma sequence does not occur between gastric adenoma and adenocarcinoma. J Pathol 176(3):249–258PubMedCrossRef
7.
Zurück zum Zitat Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, Höfler H (1994) E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 54(14):3845–3852PubMed Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, Höfler H (1994) E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 54(14):3845–3852PubMed
8.
Zurück zum Zitat Li QL, Ito K, Sakakura C, Fukamachi H, Ki I, Chi XZ et al (2002) Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109(1):113–124PubMedCrossRef Li QL, Ito K, Sakakura C, Fukamachi H, Ki I, Chi XZ et al (2002) Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109(1):113–124PubMedCrossRef
9.
Zurück zum Zitat Hirst M, Marra MA (2009) Epigenetics and human disease. Int J of Biochem Cell Bio 41(1):136–146CrossRef Hirst M, Marra MA (2009) Epigenetics and human disease. Int J of Biochem Cell Bio 41(1):136–146CrossRef
10.
Zurück zum Zitat Panani AD (2008) Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Letter 266(2):99–115CrossRef Panani AD (2008) Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Letter 266(2):99–115CrossRef
11.
Zurück zum Zitat Mulero-Navarro S, Esteller M (2008) Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol 68(1):1–11PubMedCrossRef Mulero-Navarro S, Esteller M (2008) Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol 68(1):1–11PubMedCrossRef
12.
Zurück zum Zitat Khan FA, Shukla AN (2006) Pathogenesis and treatment of gastric carcinoma: “an up-date with brief review”. J Cancer Res Ther 2(4):196–199PubMedCrossRef Khan FA, Shukla AN (2006) Pathogenesis and treatment of gastric carcinoma: “an up-date with brief review”. J Cancer Res Ther 2(4):196–199PubMedCrossRef
13.
Zurück zum Zitat Nitti D, Mocellin S, Marchet A, Pilati P, Lise M (2008) Recent advances in conventional and molecular prognostic factors for gastric carcinoma. Surg Oncol Clin N Am 17(3):467–483PubMedCrossRef Nitti D, Mocellin S, Marchet A, Pilati P, Lise M (2008) Recent advances in conventional and molecular prognostic factors for gastric carcinoma. Surg Oncol Clin N Am 17(3):467–483PubMedCrossRef
14.
Zurück zum Zitat Fan CY (2004) Epigenetic alterations in head and neck cancer: prevalence, clinical significance, and implications. Curr Oncol Rep 6(2):152–161PubMedCrossRef Fan CY (2004) Epigenetic alterations in head and neck cancer: prevalence, clinical significance, and implications. Curr Oncol Rep 6(2):152–161PubMedCrossRef
15.
Zurück zum Zitat Tischoff I, Wittekind C, Tannapfel A (2006) Role of epigenetic alterations in cholangiocarcinoma. J Hepato-Biliary-Pancreat Surg 13(4):274–279CrossRef Tischoff I, Wittekind C, Tannapfel A (2006) Role of epigenetic alterations in cholangiocarcinoma. J Hepato-Biliary-Pancreat Surg 13(4):274–279CrossRef
16.
17.
Zurück zum Zitat Bird AP (1986) CpG-rich islands and the function of DNA methylation. Nature 321(6067):209–213PubMedCrossRef Bird AP (1986) CpG-rich islands and the function of DNA methylation. Nature 321(6067):209–213PubMedCrossRef
18.
Zurück zum Zitat Nakajima T, Enomoto S, Ushijima T (2008) DNA methylation: a marker for carcinogen exposure and cancer risk. Environ Health Prev Med 13(1):8–15PubMedCrossRef Nakajima T, Enomoto S, Ushijima T (2008) DNA methylation: a marker for carcinogen exposure and cancer risk. Environ Health Prev Med 13(1):8–15PubMedCrossRef
19.
Zurück zum Zitat Chen CZ (2005) Micro-RNAs as oncogenes and tumour suppressors. N Engl J Med 353(17):1768–1771PubMedCrossRef Chen CZ (2005) Micro-RNAs as oncogenes and tumour suppressors. N Engl J Med 353(17):1768–1771PubMedCrossRef
20.
Zurück zum Zitat Calin GA, Croce CM (2006) Micro-RNA signatures in human cancers. Nat Rev Cancer 6(11):857–866PubMedCrossRef Calin GA, Croce CM (2006) Micro-RNA signatures in human cancers. Nat Rev Cancer 6(11):857–866PubMedCrossRef
21.
Zurück zum Zitat Hinshelwood RA, Clark SJ (2008) Breast cancer epigenetics: normal human mammary epithelial cells as a model system. J Mol Med 86(12):1315–1328PubMedCrossRef Hinshelwood RA, Clark SJ (2008) Breast cancer epigenetics: normal human mammary epithelial cells as a model system. J Mol Med 86(12):1315–1328PubMedCrossRef
22.
Zurück zum Zitat Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3(6):415–428PubMedCrossRef Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3(6):415–428PubMedCrossRef
23.
Zurück zum Zitat Karpf AR, Jones DA (2002) Reactivating the expression of methylation silenced genes in human cancer. Oncogene 21(35):5450–5461CrossRef Karpf AR, Jones DA (2002) Reactivating the expression of methylation silenced genes in human cancer. Oncogene 21(35):5450–5461CrossRef
24.
Zurück zum Zitat Lund AH, van Lohuizen M (2004) Polycomb complexes and silencing mechanisms. Curr Opin Cell Biol 16(3):239–246PubMedCrossRef Lund AH, van Lohuizen M (2004) Polycomb complexes and silencing mechanisms. Curr Opin Cell Biol 16(3):239–246PubMedCrossRef
25.
Zurück zum Zitat Sparmann A, van Lohuizen M (2006) Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6(11):846–856PubMedCrossRef Sparmann A, van Lohuizen M (2006) Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6(11):846–856PubMedCrossRef
26.
Zurück zum Zitat An C, Choi IS, Yao JC, Worah S, Xie K, Mansfield PF, Ajani JA, Rashid A, Hamilton SR, Wu TT (2005) Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 11(2 Pt 1):656–663PubMed An C, Choi IS, Yao JC, Worah S, Xie K, Mansfield PF, Ajani JA, Rashid A, Hamilton SR, Wu TT (2005) Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 11(2 Pt 1):656–663PubMed
27.
Zurück zum Zitat Song SH, Jong HS, Choi HH, Kang SH, Ryu MH, Kim NK, Kim WH, Bang YJ (2000) Methylation of specific CpG sites in the promoter region could significantly down-regulate p16 (INK4a) expression in gastric adenocarcinoma. Int J Cancer 87(2):236–240PubMedCrossRef Song SH, Jong HS, Choi HH, Kang SH, Ryu MH, Kim NK, Kim WH, Bang YJ (2000) Methylation of specific CpG sites in the promoter region could significantly down-regulate p16 (INK4a) expression in gastric adenocarcinoma. Int J Cancer 87(2):236–240PubMedCrossRef
28.
Zurück zum Zitat Guimarães AC, Lima EM, Khayat AS, Girão Faria MH, Barem Rabenhorst SH, Pitombeira MV, Assumpção PP, de Oliveira Bahia M, Lima de Lima PD, de Arruda Cardoso Smith M, Burbano RR (2007) Interrelationships among chromosome aneuploidy, promoter hypermethylation, and protein expression of the CDKN2A gene in individuals from northern Brazil with gastric adenocarcinoma. Cancer Genet Cytogenet 179(1):45–51PubMedCrossRef Guimarães AC, Lima EM, Khayat AS, Girão Faria MH, Barem Rabenhorst SH, Pitombeira MV, Assumpção PP, de Oliveira Bahia M, Lima de Lima PD, de Arruda Cardoso Smith M, Burbano RR (2007) Interrelationships among chromosome aneuploidy, promoter hypermethylation, and protein expression of the CDKN2A gene in individuals from northern Brazil with gastric adenocarcinoma. Cancer Genet Cytogenet 179(1):45–51PubMedCrossRef
29.
Zurück zum Zitat Lee JH, Park SJ, Abraham SC, Seo JS, Nam JH, Choi C, Juhng SW, Rashid A, Hamilton SR, Wu TT (2004) Frequent CpG island methylation in precursor lesions and early gastric adenocarcinomas. Oncogene 23(26):4646–4654PubMedCrossRef Lee JH, Park SJ, Abraham SC, Seo JS, Nam JH, Choi C, Juhng SW, Rashid A, Hamilton SR, Wu TT (2004) Frequent CpG island methylation in precursor lesions and early gastric adenocarcinomas. Oncogene 23(26):4646–4654PubMedCrossRef
30.
Zurück zum Zitat Fleisher AS, Esteller M, Wang S, Tamura G, Suzuki H, Yin J, Zou TT, Abraham JM, Kong D, Smolinski KN, Shi YQ, Rhyu MG, Powell SM, James SP, Wilson KT, Herman JG, Meltzer SJ (1999) Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 59(5):1090–1095PubMed Fleisher AS, Esteller M, Wang S, Tamura G, Suzuki H, Yin J, Zou TT, Abraham JM, Kong D, Smolinski KN, Shi YQ, Rhyu MG, Powell SM, James SP, Wilson KT, Herman JG, Meltzer SJ (1999) Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 59(5):1090–1095PubMed
31.
Zurück zum Zitat Leung SY, Yuen ST, Chung LP, Chu KM, Chan AS, Ho JC (1999) hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res 59(1):159–164PubMed Leung SY, Yuen ST, Chung LP, Chu KM, Chan AS, Ho JC (1999) hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res 59(1):159–164PubMed
32.
Zurück zum Zitat Jung HY, Jung KC, Shim YH, Ro JY, Kang GH (2001) Methylation of the hMLH1 promoter in multiple gastric carcinomas with microsatellite instability. Pathol Int 51(6):445–451PubMedCrossRef Jung HY, Jung KC, Shim YH, Ro JY, Kang GH (2001) Methylation of the hMLH1 promoter in multiple gastric carcinomas with microsatellite instability. Pathol Int 51(6):445–451PubMedCrossRef
33.
Zurück zum Zitat Oue N, Shigeishi H, Kuniyasu H, Yokozaki H, Kuraoka K, Ito R, Yasui W (2001) Promoter hypermethylation of MGMT is associated with protein loss in gastric carcinoma. Int J Cancer 93(6):805–809PubMedCrossRef Oue N, Shigeishi H, Kuniyasu H, Yokozaki H, Kuraoka K, Ito R, Yasui W (2001) Promoter hypermethylation of MGMT is associated with protein loss in gastric carcinoma. Int J Cancer 93(6):805–809PubMedCrossRef
34.
Zurück zum Zitat Zazula M, Ferreira AM, Czopek JP, Kolodziejczyk P, Sinczak-Kuta A, Klimkowska A, Wojcik P, Okon K, Bialas M, Kulig J, Stachura J (2006) CDH1 gene promoter hypermethylation in gastric cancer: relationship to Goseki grading, microsatellite instability status, and EBV invasion. Diagn Mol Pathol 15(1):24–29PubMedCrossRef Zazula M, Ferreira AM, Czopek JP, Kolodziejczyk P, Sinczak-Kuta A, Klimkowska A, Wojcik P, Okon K, Bialas M, Kulig J, Stachura J (2006) CDH1 gene promoter hypermethylation in gastric cancer: relationship to Goseki grading, microsatellite instability status, and EBV invasion. Diagn Mol Pathol 15(1):24–29PubMedCrossRef
35.
Zurück zum Zitat Graziano F, Arduini F, Ruzzo A, Bearzi I, Humar B, More H, Silva R, Muretto P, Guilford P, Testa E, Mari D, Magnani M, Cascinu S (2004) Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer. Clin Cancer Res 10(8):2784–2789PubMedCrossRef Graziano F, Arduini F, Ruzzo A, Bearzi I, Humar B, More H, Silva R, Muretto P, Guilford P, Testa E, Mari D, Magnani M, Cascinu S (2004) Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer. Clin Cancer Res 10(8):2784–2789PubMedCrossRef
36.
Zurück zum Zitat Liu WT, Jiao HL, Yang YL, Wang D, Zhang WM (2007) Correlation of E-cadherin hypermethylation to tumorigenesis and development of gastric cancer. Ai Zheng 26(11):1199–1203PubMed Liu WT, Jiao HL, Yang YL, Wang D, Zhang WM (2007) Correlation of E-cadherin hypermethylation to tumorigenesis and development of gastric cancer. Ai Zheng 26(11):1199–1203PubMed
37.
Zurück zum Zitat Terrés AM, Pajares JM, O'Toole D, Ahern S, Kelleher D (1998) Helicobacter pylori infection is associated with downregulation of E-cadherin, a molecule involved in epithelial cell adhesion and proliferation control. J Clin Pathol 51(5):410–412PubMedPubMedCentralCrossRef Terrés AM, Pajares JM, O'Toole D, Ahern S, Kelleher D (1998) Helicobacter pylori infection is associated with downregulation of E-cadherin, a molecule involved in epithelial cell adhesion and proliferation control. J Clin Pathol 51(5):410–412PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Chan AO, Lam SK, Wong BC, Wong WM, Yuen MF, Yeung YH, Hui WM, Rashid A, Kwong YL (2003) Promoter methylation of E-cadherin gene in gastric mucosa associated with helicobacter pylori infection and in gastric cancer. Gut 52(4):502–506PubMedPubMedCentralCrossRef Chan AO, Lam SK, Wong BC, Wong WM, Yuen MF, Yeung YH, Hui WM, Rashid A, Kwong YL (2003) Promoter methylation of E-cadherin gene in gastric mucosa associated with helicobacter pylori infection and in gastric cancer. Gut 52(4):502–506PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Chan AW, Chan MW, Lee TL, Ng EK, Leung WK, Lau JY, Tong JH, Chan FK, To KF (2005) Promoter hypermethylation of death associated protein-kinase gene associated with advance stage gastric cancer. Oncol Rep 13(5):937–941PubMed Chan AW, Chan MW, Lee TL, Ng EK, Leung WK, Lau JY, Tong JH, Chan FK, To KF (2005) Promoter hypermethylation of death associated protein-kinase gene associated with advance stage gastric cancer. Oncol Rep 13(5):937–941PubMed
41.
Zurück zum Zitat Byun DS, Lee MG, Chae KS, Ryu BG, Chi SG (2001) Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res 61(19):7034–7038PubMed Byun DS, Lee MG, Chae KS, Ryu BG, Chi SG (2001) Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res 61(19):7034–7038PubMed
42.
Zurück zum Zitat Balgkouranidou I, Matthaios D, Karayiannakis A, Bolanaki H, Michailidis P, Xenidis N, Amarantidis K, Chelis L, Trypsianis G, Chatzaki E, Lianidou ES, Kakolyris S (2015) Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients. Mutat Res 778:46–51PubMedCrossRef Balgkouranidou I, Matthaios D, Karayiannakis A, Bolanaki H, Michailidis P, Xenidis N, Amarantidis K, Chelis L, Trypsianis G, Chatzaki E, Lianidou ES, Kakolyris S (2015) Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients. Mutat Res 778:46–51PubMedCrossRef
43.
Zurück zum Zitat Dote H, Toyooka S, Tsukuda K, Yano M, Ota T, Murakami M, Naito M, Toyota M, Gazdar AF, Shimizu N (2005) Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour. Br J Cancer 92(6):1117–1125PubMedPubMedCentralCrossRef Dote H, Toyooka S, Tsukuda K, Yano M, Ota T, Murakami M, Naito M, Toyota M, Gazdar AF, Shimizu N (2005) Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour. Br J Cancer 92(6):1117–1125PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Byun DS, Cho K, Ryu BK, Lee MG, Kang MJ, Kim HR, Chi SG (2003) Hypermethylation of XIAP associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res 63(21):7068–7075PubMed Byun DS, Cho K, Ryu BK, Lee MG, Kang MJ, Kim HR, Chi SG (2003) Hypermethylation of XIAP associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res 63(21):7068–7075PubMed
46.
Zurück zum Zitat Jee CD, Lee HS, Bae SI, Yang HK, Lee YM, Rho MS, Kim WH (2005) Loss of caspase-1 gene expression in human gastric carcinomas and cell lines. Int J Oncol 26(5):1265–1271PubMed Jee CD, Lee HS, Bae SI, Yang HK, Lee YM, Rho MS, Kim WH (2005) Loss of caspase-1 gene expression in human gastric carcinomas and cell lines. Int J Oncol 26(5):1265–1271PubMed
47.
Zurück zum Zitat Jung Y, Park J, Bang YJ, Kim TY (2008) Gene silencing of TSPYL5 mediated by aberrant promoter methylation in gastric cancers. Lab Investig 88(2):153–160PubMedCrossRef Jung Y, Park J, Bang YJ, Kim TY (2008) Gene silencing of TSPYL5 mediated by aberrant promoter methylation in gastric cancers. Lab Investig 88(2):153–160PubMedCrossRef
48.
Zurück zum Zitat Lee JH, Byun DS, Lee MG, Ryu BK, Kang MJ, Chae KS, Lee KY, Kim HJ, Park H, Chi SG (2008) Frequent epigenetic inactivation of hSRBC in gastric cancer and its implication in attenuated p53 response to stresses. Int J Cancer 122(7):1573–1584PubMedCrossRef Lee JH, Byun DS, Lee MG, Ryu BK, Kang MJ, Chae KS, Lee KY, Kim HJ, Park H, Chi SG (2008) Frequent epigenetic inactivation of hSRBC in gastric cancer and its implication in attenuated p53 response to stresses. Int J Cancer 122(7):1573–1584PubMedCrossRef
49.
Zurück zum Zitat Cheng YY, Yu J, Wong YP, Man EP, To KF, Jin VX, Li J, Tao Q, Sung JJ, Chan FK, Leung WK (2007) Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer. Br J Cancer 97(7):895–901PubMedPubMedCentralCrossRef Cheng YY, Yu J, Wong YP, Man EP, To KF, Jin VX, Li J, Tao Q, Sung JJ, Chan FK, Leung WK (2007) Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer. Br J Cancer 97(7):895–901PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat Sato H, Suzuki H, Toyota M, Nojima M, Maruyama R, Sasaki S, Takagi H, Sogabe Y, Sasaki Y, Idogawa M, Sonoda T, Mori M, Imai K, Tokino T, Shinomura Y (2007) Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumours. Carcinogenesis 28(12):2459–2466PubMedCrossRef Sato H, Suzuki H, Toyota M, Nojima M, Maruyama R, Sasaki S, Takagi H, Sogabe Y, Sasaki Y, Idogawa M, Sonoda T, Mori M, Imai K, Tokino T, Shinomura Y (2007) Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumours. Carcinogenesis 28(12):2459–2466PubMedCrossRef
51.
Zurück zum Zitat Nojima M, Suzuki H, Toyota M, Watanabe Y, Maruyama R, Sasaki S, Sasaki Y, Mita H, Nishikawa N, Yamaguchi K, Hirata K, Itoh F, Tokino T, Mori M, Imai K, Shinomura Y (2007) Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene 26(32):4699–4713PubMedCrossRef Nojima M, Suzuki H, Toyota M, Watanabe Y, Maruyama R, Sasaki S, Sasaki Y, Mita H, Nishikawa N, Yamaguchi K, Hirata K, Itoh F, Tokino T, Mori M, Imai K, Shinomura Y (2007) Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene 26(32):4699–4713PubMedCrossRef
52.
Zurück zum Zitat Ebert MP, Yu J, Hoffmann J, Rocco A, Röcken C, Kahmann S, Müller O, Korc M, Sung JJ, Malfertheiner P (2003) Loss of beta-catenin expression in metastatic gastric cancer. J Clin Oncol 21(9):1708–1714PubMedCrossRef Ebert MP, Yu J, Hoffmann J, Rocco A, Röcken C, Kahmann S, Müller O, Korc M, Sung JJ, Malfertheiner P (2003) Loss of beta-catenin expression in metastatic gastric cancer. J Clin Oncol 21(9):1708–1714PubMedCrossRef
53.
Zurück zum Zitat Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H, Tian LW, Wong YP, Tong JH, Ying JM, Jin H, To KF, Chan FK, Sung JJ (2009) Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology 136(2):640–651PubMedCrossRef Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H, Tian LW, Wong YP, Tong JH, Ying JM, Jin H, To KF, Chan FK, Sung JJ (2009) Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology 136(2):640–651PubMedCrossRef
54.
Zurück zum Zitat Takada H, Imoto I, Tsuda H, Nakanishi Y, Sakakura C, Mitsufuji S, Hirohashi S, Inazawa J (2006) Genomic loss and epigenetic silencing of very-low-density lipoprotein receptor involved in gastric carcinogenesis. Oncogene 25(49):6554–6562PubMedCrossRef Takada H, Imoto I, Tsuda H, Nakanishi Y, Sakakura C, Mitsufuji S, Hirohashi S, Inazawa J (2006) Genomic loss and epigenetic silencing of very-low-density lipoprotein receptor involved in gastric carcinogenesis. Oncogene 25(49):6554–6562PubMedCrossRef
55.
Zurück zum Zitat Choi MC, Jong HS, Kim TY, Song SH, Lee DS, Lee JW, Kim TY, Kim NK, Bang YJ (2004) ACAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity. Oncogene 23(42):7095–7103PubMedCrossRef Choi MC, Jong HS, Kim TY, Song SH, Lee DS, Lee JW, Kim TY, Kim NK, Bang YJ (2004) ACAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity. Oncogene 23(42):7095–7103PubMedCrossRef
56.
Zurück zum Zitat Oshimo Y, Oue N, Mitani Y, Nakayama H, Kitadai Y, Yoshida K, Chayama K, Yasui W (2004) Frequent epigenetic inactivation of RIZ1 by promoter hypermethylation in human gastric carcinoma. Int J Cancer 110(2):212–218PubMedCrossRef Oshimo Y, Oue N, Mitani Y, Nakayama H, Kitadai Y, Yoshida K, Chayama K, Yasui W (2004) Frequent epigenetic inactivation of RIZ1 by promoter hypermethylation in human gastric carcinoma. Int J Cancer 110(2):212–218PubMedCrossRef
57.
Zurück zum Zitat Yamamichi N, Inada K, Ichinose M, Yamamichi-Nishina M, Mizutani T, Watanabe H, Shiogama K, Fujishiro M, Okazaki T, Yahagi N, Haraguchi T, Fujita S, Tsutsumi Y, Omata M, Iba H (2007) Frequent loss of Brm expression in gastric cancer correlates with histologic features and differentiation state. Cancer Res 67(22):10727–10735PubMedCrossRef Yamamichi N, Inada K, Ichinose M, Yamamichi-Nishina M, Mizutani T, Watanabe H, Shiogama K, Fujishiro M, Okazaki T, Yahagi N, Haraguchi T, Fujita S, Tsutsumi Y, Omata M, Iba H (2007) Frequent loss of Brm expression in gastric cancer correlates with histologic features and differentiation state. Cancer Res 67(22):10727–10735PubMedCrossRef
58.
Zurück zum Zitat Hamai Y, Oue N, Mitani Y, Nakayama H, Ito R, Matsusaki K, Yoshida K, Toge T, Yasui W (2003) DNA hypermethylation and histone hypoacetylation of the HLTF gene are associated with reduced expression in gastric carcinoma. Cancer Sci 94(8):692–698PubMedCrossRef Hamai Y, Oue N, Mitani Y, Nakayama H, Ito R, Matsusaki K, Yoshida K, Toge T, Yasui W (2003) DNA hypermethylation and histone hypoacetylation of the HLTF gene are associated with reduced expression in gastric carcinoma. Cancer Sci 94(8):692–698PubMedCrossRef
59.
Zurück zum Zitat Kim TY, Lee HJ, Hwang KS, Lee M, Kim JW, Bang YJ, Kang GH (2004) Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Investig 84(4):479–484PubMedCrossRef Kim TY, Lee HJ, Hwang KS, Lee M, Kim JW, Bang YJ, Kang GH (2004) Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Investig 84(4):479–484PubMedCrossRef
60.
Zurück zum Zitat Hayashi K, Yokozaki H, Goodison S, Oue N, Suzuki T, Lotan R, Yasui W, Tahara E (2001) Inactivation of retinoic acid receptor beta by promoter CpG hypermethylation in gastric cancer. Differentiation 68(1):13–21PubMedCrossRef Hayashi K, Yokozaki H, Goodison S, Oue N, Suzuki T, Lotan R, Yasui W, Tahara E (2001) Inactivation of retinoic acid receptor beta by promoter CpG hypermethylation in gastric cancer. Differentiation 68(1):13–21PubMedCrossRef
61.
Zurück zum Zitat Oue N, Matsumura S, Nakayama H, Kitadai Y, Taniyama K, Matsusaki K, Yasui W (2003) Reduced expression of the TSP1 gene and its association with promoter hypermethylation in gastric carcinoma. Oncology 64(4):423–439PubMedCrossRef Oue N, Matsumura S, Nakayama H, Kitadai Y, Taniyama K, Matsusaki K, Yasui W (2003) Reduced expression of the TSP1 gene and its association with promoter hypermethylation in gastric carcinoma. Oncology 64(4):423–439PubMedCrossRef
62.
Zurück zum Zitat Kim TY, Jong HS, Song SH, dimtchev A, Jeong SJ, Lee JW, Kim TY, Kim NK, Jung M, Bang YJ (2003) Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. Oncogene 22(25):3943–3951PubMedCrossRef Kim TY, Jong HS, Song SH, dimtchev A, Jeong SJ, Lee JW, Kim TY, Kim NK, Jung M, Bang YJ (2003) Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. Oncogene 22(25):3943–3951PubMedCrossRef
63.
Zurück zum Zitat de Maat MF, van de Velde CJ, Umetani N, de Heer P, Putter H, van Hoesel AQ, Meijer GA, van Grieken NC, Kuppen PJ, Bilchik AJ, Tollenaar RA, Hoon DS (2007) Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. J Clin Oncol 25(31):4887–4894PubMedCrossRef de Maat MF, van de Velde CJ, Umetani N, de Heer P, Putter H, van Hoesel AQ, Meijer GA, van Grieken NC, Kuppen PJ, Bilchik AJ, Tollenaar RA, Hoon DS (2007) Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. J Clin Oncol 25(31):4887–4894PubMedCrossRef
64.
Zurück zum Zitat Poplawski T, tomaszewska K, Galicki M, Morawiec Z, Blasiak J (2008) Promoter methylation of cancer related genes in gastric carcinoma. Exp Oncol 30(2):112–116PubMed Poplawski T, tomaszewska K, Galicki M, Morawiec Z, Blasiak J (2008) Promoter methylation of cancer related genes in gastric carcinoma. Exp Oncol 30(2):112–116PubMed
65.
Zurück zum Zitat Kang GH, Lee S, Kim JS, Jung HY (2003) Profile of aberrant CpG island methylation along multistep gastric carcinogenesis. Lab Investig 83(4):519–526PubMedCrossRef Kang GH, Lee S, Kim JS, Jung HY (2003) Profile of aberrant CpG island methylation along multistep gastric carcinogenesis. Lab Investig 83(4):519–526PubMedCrossRef
66.
Zurück zum Zitat Oue N, Motoshita J, Yokozaki H, Hayashi K, Tahara E, Taniyama K, Matsusaki K, Yasui W (2002) Distinct promoter hypermethylation of p16INK4a, CDH1, and RAR-beta in intestinal, diffuse-adherent, and diffuse-scattered type gastric carcinomas. J Pathol 198(1):55–59PubMedCrossRef Oue N, Motoshita J, Yokozaki H, Hayashi K, Tahara E, Taniyama K, Matsusaki K, Yasui W (2002) Distinct promoter hypermethylation of p16INK4a, CDH1, and RAR-beta in intestinal, diffuse-adherent, and diffuse-scattered type gastric carcinomas. J Pathol 198(1):55–59PubMedCrossRef
67.
Zurück zum Zitat Sepulveda JL, Gutierrez-Pajares JL, Luna A, Yao Y, Tobias JW, Thomas S, Woo Y, Giorgi F, Komissarova EV, Califano A, Wang TC, Sepulveda AR (2016) High-definition CpG methylation of novel genes in gastric carcinogenesis identified by next-generation sequencing. Mod Pathol 29(2):182–193PubMedCrossRef Sepulveda JL, Gutierrez-Pajares JL, Luna A, Yao Y, Tobias JW, Thomas S, Woo Y, Giorgi F, Komissarova EV, Califano A, Wang TC, Sepulveda AR (2016) High-definition CpG methylation of novel genes in gastric carcinogenesis identified by next-generation sequencing. Mod Pathol 29(2):182–193PubMedCrossRef
68.
Zurück zum Zitat Honda T, Tamura G, Waki T, Kawata S, Terashima M, Nishizuka S, Motoyama T (2004) Demethylation of MAGE promoters during gastric cancer progression. Br J Cancer 90(4):838–843PubMedPubMedCentralCrossRef Honda T, Tamura G, Waki T, Kawata S, Terashima M, Nishizuka S, Motoyama T (2004) Demethylation of MAGE promoters during gastric cancer progression. Br J Cancer 90(4):838–843PubMedPubMedCentralCrossRef
69.
Zurück zum Zitat Yanagawa N, Tamura G, Honda T, Endoh M, Nishizuka S, Motoyama T (2004) Demethylation of the synuclein gamma gene CpG island in primary gastric cancers and gastric cancer cell lines. Clin Cancer Res 10(7):2447–2451PubMedCrossRef Yanagawa N, Tamura G, Honda T, Endoh M, Nishizuka S, Motoyama T (2004) Demethylation of the synuclein gamma gene CpG island in primary gastric cancers and gastric cancer cell lines. Clin Cancer Res 10(7):2447–2451PubMedCrossRef
70.
Zurück zum Zitat Lima EM, Leal MF, Burbano RR, Khayat AS, Assumpcao PP, Bello MJ, Rey JA, Smith MA, Casartelli C (2008) Methylation status of ANAPC1, CDKN2A and TP53 promoter genes in individuals with gastric cancer. Braz J Med Biol Res 41(6):539–543PubMedCrossRef Lima EM, Leal MF, Burbano RR, Khayat AS, Assumpcao PP, Bello MJ, Rey JA, Smith MA, Casartelli C (2008) Methylation status of ANAPC1, CDKN2A and TP53 promoter genes in individuals with gastric cancer. Braz J Med Biol Res 41(6):539–543PubMedCrossRef
71.
Zurück zum Zitat Heard E, Rougeulle C, Arnaud D, Avner P, Allis CD, Spector DL (2001) Methylation of histone H3 at Lys-9 is an early mark on the X chromosome during X inactivation. Cell 107(6):727–738PubMedCrossRef Heard E, Rougeulle C, Arnaud D, Avner P, Allis CD, Spector DL (2001) Methylation of histone H3 at Lys-9 is an early mark on the X chromosome during X inactivation. Cell 107(6):727–738PubMedCrossRef
72.
Zurück zum Zitat Mermoud JE, Popova B, Peters AH, Jenuwein T, Brockdorff N (2002) Histone H3 lysine 9 methylation occurs rapidly at the onset of random X chromosome inactivation. Curr Biol 12(3):247–251PubMedCrossRef Mermoud JE, Popova B, Peters AH, Jenuwein T, Brockdorff N (2002) Histone H3 lysine 9 methylation occurs rapidly at the onset of random X chromosome inactivation. Curr Biol 12(3):247–251PubMedCrossRef
73.
Zurück zum Zitat Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, Liang G, Jones PA (2002) Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Res 62(22):6456–6461PubMed Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, Liang G, Jones PA (2002) Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Res 62(22):6456–6461PubMed
74.
Zurück zum Zitat Schotta G, Lachner M, Sarma K, Ebert A, Sengupta R, Reuter G, Reinberg D, Jenuwein T (2004) A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev 18(11):1251–1262PubMedPubMedCentralCrossRef Schotta G, Lachner M, Sarma K, Ebert A, Sengupta R, Reuter G, Reinberg D, Jenuwein T (2004) A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev 18(11):1251–1262PubMedPubMedCentralCrossRef
75.
Zurück zum Zitat Park YS, Jin MY, Kim YJ, Yook JH, Kim BS, Jang SJ (2008) The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol 15(7):1968–1976PubMedCrossRef Park YS, Jin MY, Kim YJ, Yook JH, Kim BS, Jang SJ (2008) The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol 15(7):1968–1976PubMedCrossRef
76.
Zurück zum Zitat Kondo Y, Shen L, Issa JP (2003) Critical role of histone methylation in tumour suppressor gene silencing in colorectal cancer. Mol Cell Biol 23(1):206–215PubMedPubMedCentralCrossRef Kondo Y, Shen L, Issa JP (2003) Critical role of histone methylation in tumour suppressor gene silencing in colorectal cancer. Mol Cell Biol 23(1):206–215PubMedPubMedCentralCrossRef
77.
Zurück zum Zitat Watanabe Y, Toyota M, Kondo Y, Suzuki H, Imai T, Ohe-Toyota M, Maruyama R, Nojima M, Sasaki Y, Sekido Y, Hiratsuka H, Shinomura Y, Imai K, Itoh F, Tokino T (2007) PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer. Clin Cancer Res 13(16):4786–4794PubMedCrossRef Watanabe Y, Toyota M, Kondo Y, Suzuki H, Imai T, Ohe-Toyota M, Maruyama R, Nojima M, Sasaki Y, Sekido Y, Hiratsuka H, Shinomura Y, Imai K, Itoh F, Tokino T (2007) PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer. Clin Cancer Res 13(16):4786–4794PubMedCrossRef
78.
Zurück zum Zitat Ono S, Oue N, Kuniyasu H, Suzuki T, Ito R, Matsusaki K, Ishikawa T, Tahara E, Yasui W (2002) Acetylated histone H4 is reduced in human gastric adenomas and carcinomas. J Exp Clin Cancer Res 21(3):377–382PubMed Ono S, Oue N, Kuniyasu H, Suzuki T, Ito R, Matsusaki K, Ishikawa T, Tahara E, Yasui W (2002) Acetylated histone H4 is reduced in human gastric adenomas and carcinomas. J Exp Clin Cancer Res 21(3):377–382PubMed
79.
Zurück zum Zitat Mitani Y, Oue N, Hamai Y, Aung PP, Matsumura S, Nakayama H, Kamata N, Yasui W (2005) Histone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma. J Pathol 205(1):65–73PubMedCrossRef Mitani Y, Oue N, Hamai Y, Aung PP, Matsumura S, Nakayama H, Kamata N, Yasui W (2005) Histone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma. J Pathol 205(1):65–73PubMedCrossRef
80.
Zurück zum Zitat Xia G, Schneider-Stock R, Diestel A, Habold C, Krueger S, Roessner A, Naumann M, Lendeckel U (2008) Helicobacter pylori regulates p21(WAF1) by histone H4 acetylation. Biochem Biophys Res Commun 369(2):526–531PubMedCrossRef Xia G, Schneider-Stock R, Diestel A, Habold C, Krueger S, Roessner A, Naumann M, Lendeckel U (2008) Helicobacter pylori regulates p21(WAF1) by histone H4 acetylation. Biochem Biophys Res Commun 369(2):526–531PubMedCrossRef
81.
82.
Zurück zum Zitat Tekcham DS, Tiwari PK (2016) Non-coding RNAs as emerging molecular targets in gallbladder cancer. Gene 588(1):79–85PubMedCrossRef Tekcham DS, Tiwari PK (2016) Non-coding RNAs as emerging molecular targets in gallbladder cancer. Gene 588(1):79–85PubMedCrossRef
86.
Zurück zum Zitat Li CL, Nie H, Wang M, Su LP, Li JF, Yu YY, Yan M, Qu QL, Zhu ZG, Liu BY (2012) microRNA-155 is downregulated in gastric cancer cells and involved in cell metastasis. Oncol Rep 27(6):1960–1966PubMed Li CL, Nie H, Wang M, Su LP, Li JF, Yu YY, Yan M, Qu QL, Zhu ZG, Liu BY (2012) microRNA-155 is downregulated in gastric cancer cells and involved in cell metastasis. Oncol Rep 27(6):1960–1966PubMed
88.
Zurück zum Zitat Tsai KW, Liao YL, Wu CW, Hu LY, Li SC, Chan WC, Ho MR, Lai CH, Kao HW, Fang WL, Huang KH, Lin WC (2011) Aberrant hypermethylation of miR-9 genes in gastric cancer. Epigenetics 6(10):1189–1197PubMedPubMedCentralCrossRef Tsai KW, Liao YL, Wu CW, Hu LY, Li SC, Chan WC, Ho MR, Lai CH, Kao HW, Fang WL, Huang KH, Lin WC (2011) Aberrant hypermethylation of miR-9 genes in gastric cancer. Epigenetics 6(10):1189–1197PubMedPubMedCentralCrossRef
89.
Zurück zum Zitat Chen Q, Chen X, Zhang M, Fan Q, Luo S, Cao X (2011) miR-137 is frequently down-regulated in gastric cancer and is a negative regulator of Cdc42. Dig Dis Sci 56(7):2009–2016PubMedCrossRef Chen Q, Chen X, Zhang M, Fan Q, Luo S, Cao X (2011) miR-137 is frequently down-regulated in gastric cancer and is a negative regulator of Cdc42. Dig Dis Sci 56(7):2009–2016PubMedCrossRef
90.
Zurück zum Zitat Deng H, Guo Y, Song H, Xiao B, Sun W, Liu Z, Yu X, Xia T, Cui L, Guo J (2013) MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene 518(2):351–359PubMedCrossRef Deng H, Guo Y, Song H, Xiao B, Sun W, Liu Z, Yu X, Xia T, Cui L, Guo J (2013) MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene 518(2):351–359PubMedCrossRef
91.
Zurück zum Zitat Wei B, Song Y, Zhang Y, Hu M (2013) microRNA-449a functions as a tumor-suppressor in gastric adenocarcinoma by targeting Bcl-2. Oncol Lett 6(6):1713–1718PubMedPubMedCentralCrossRef Wei B, Song Y, Zhang Y, Hu M (2013) microRNA-449a functions as a tumor-suppressor in gastric adenocarcinoma by targeting Bcl-2. Oncol Lett 6(6):1713–1718PubMedPubMedCentralCrossRef
92.
Zurück zum Zitat Ding L, Xu Y, Zhang W, Deng Y, Si M, Du Y, Yao H, Liu X, Ke Y, Si J, Zhou T (2010) MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res 20(7):784–793PubMedCrossRef Ding L, Xu Y, Zhang W, Deng Y, Si M, Du Y, Yao H, Liu X, Ke Y, Si J, Zhou T (2010) MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res 20(7):784–793PubMedCrossRef
93.
Zurück zum Zitat Niinuma T, Suzuki H, Nojima M, Nosho K, Yamamoto H, Takamaru H, Yamamoto E, Maruyama R, Nobuoka T, Miyazaki Y, Nishida T, Bamba T, Kanda T, Ajioka Y, Taguchi T, Okahara S, Takahashi H, Nishida Y, Hosokawa M, Hasegawa T, Tokino T, Hirata K, Imai K, Toyota M, Shinomura Y (2012) Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. Cancer Res 72(5):1126–1136PubMedCrossRef Niinuma T, Suzuki H, Nojima M, Nosho K, Yamamoto H, Takamaru H, Yamamoto E, Maruyama R, Nobuoka T, Miyazaki Y, Nishida T, Bamba T, Kanda T, Ajioka Y, Taguchi T, Okahara S, Takahashi H, Nishida Y, Hosokawa M, Hasegawa T, Tokino T, Hirata K, Imai K, Toyota M, Shinomura Y (2012) Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. Cancer Res 72(5):1126–1136PubMedCrossRef
94.
Zurück zum Zitat Wu H, Huang M, Lu M, Zhu W, Shu Y, Cao P, Liu P (2013) Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel. Cancer Chemother Pharmacol 71(5):1159–1171PubMedCrossRef Wu H, Huang M, Lu M, Zhu W, Shu Y, Cao P, Liu P (2013) Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel. Cancer Chemother Pharmacol 71(5):1159–1171PubMedCrossRef
95.
Zurück zum Zitat Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J, Jiang B, Shu Y, Liu P (2012) miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 69(3):723–731PubMedCrossRef Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J, Jiang B, Shu Y, Liu P (2012) miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 69(3):723–731PubMedCrossRef
96.
Zurück zum Zitat Eddy SR (2001) Non–coding RNA genes and the modern RNA world. Nat Rev Genet 2(12):919–929PubMedCrossRef Eddy SR (2001) Non–coding RNA genes and the modern RNA world. Nat Rev Genet 2(12):919–929PubMedCrossRef
97.
Zurück zum Zitat S D, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A et al (2012) Landscape of transcription in human cells. Nature 489(7414):101–108CrossRef S D, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A et al (2012) Landscape of transcription in human cells. Nature 489(7414):101–108CrossRef
98.
Zurück zum Zitat Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, Oyama R, Ravasi T, Lenhard B, Wells C, Kodzius R, Shimokawa K, Bajic VB, Brenner SE, Batalov S, Forrest AR, Zavolan M, Davis MJ, Wilming LG, Aidinis V, Allen JE, Ambesi-Impiombato A, Apweiler R, Aturaliya RN, Bailey TL, Bansal M, Baxter L, Beisel KW, Bersano T, Bono H, Chalk AM, Chiu KP, Choudhary V, Christoffels A, Clutterbuck DR, Crowe ML, Dalla E, Dalrymple BP, de Bono B, Della Gatta G, di Bernardo D, Down T, Engstrom P, Fagiolini M, Faulkner G, Fletcher CF, Fukushima T, Furuno M, Futaki S, Gariboldi M, Georgii-Hemming P, Gingeras TR, Gojobori T, Green RE, Gustincich S, Harbers M, Hayashi Y, Hensch TK, Hirokawa N, Hill D, Huminiecki L, Iacono M, Ikeo K, Iwama A, Ishikawa T, Jakt M, Kanapin A, Katoh M, Kawasawa Y, Kelso J, Kitamura H, Kitano H, Kollias G, Krishnan SP, Kruger A, Kummerfeld SK, Kurochkin IV, Lareau LF, Lazarevic D, Lipovich L, Liu J, Liuni S, McWilliam S, Madan Babu M, Madera M, Marchionni L, Matsuda H, Matsuzawa S, Miki H, Mignone F, Miyake S, Morris K, Mottagui-Tabar S, Mulder N, Nakano N, Nakauchi H, Ng P, Nilsson R, Nishiguchi S, Nishikawa S, Nori F, Ohara O, Okazaki Y, Orlando V, Pang KC, Pavan WJ, Pavesi G, Pesole G, Petrovsky N, Piazza S, Reed J, Reid JF, Ring BZ, Ringwald M, Rost B, Ruan Y, Salzberg SL, Sandelin A, Schneider C, Schönbach C, Sekiguchi K, Semple CA, Seno S, Sessa L, Sheng Y, Shibata Y, Shimada H, Shimada K, Silva D, Sinclair B, Sperling S, Stupka E, Sugiura K, Sultana R, Takenaka Y, Taki K, Tammoja K, Tan SL, Tang S, Taylor MS, Tegner J, Teichmann SA, Ueda HR, van Nimwegen E, Verardo R, Wei CL, Yagi K, Yamanishi H, Zabarovsky E, Zhu S, Zimmer A, Hide W, Bult C, Grimmond SM, Teasdale RD, Liu ET, Brusic V, Quackenbush J, Wahlestedt C, Mattick JS, Hume DA, Kai C, Sasaki D, Tomaru Y, Fukuda S, Kanamori-Katayama M, Suzuki M, Aoki J, Arakawa T, Iida J, Imamura K, Itoh M, Kato T, Kawaji H, Kawagashira N, Kawashima T, Kojima M, Kondo S, Konno H, Nakano K, Ninomiya N, Nishio T, Okada M, Plessy C, Shibata K, Shiraki T, Suzuki S, Tagami M, Waki K, Watahiki A, Okamura-Oho Y, Suzuki H, Kawai J, Hayashizaki Y, FANTOM Consortium, RIKEN Genome Exploration Research Group and Genome Science Group (Genome Network Project Core Group) (2005) The transcriptional landscape of the mammalian genome. Science 309(5740):1559–1563PubMedCrossRef Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, Oyama R, Ravasi T, Lenhard B, Wells C, Kodzius R, Shimokawa K, Bajic VB, Brenner SE, Batalov S, Forrest AR, Zavolan M, Davis MJ, Wilming LG, Aidinis V, Allen JE, Ambesi-Impiombato A, Apweiler R, Aturaliya RN, Bailey TL, Bansal M, Baxter L, Beisel KW, Bersano T, Bono H, Chalk AM, Chiu KP, Choudhary V, Christoffels A, Clutterbuck DR, Crowe ML, Dalla E, Dalrymple BP, de Bono B, Della Gatta G, di Bernardo D, Down T, Engstrom P, Fagiolini M, Faulkner G, Fletcher CF, Fukushima T, Furuno M, Futaki S, Gariboldi M, Georgii-Hemming P, Gingeras TR, Gojobori T, Green RE, Gustincich S, Harbers M, Hayashi Y, Hensch TK, Hirokawa N, Hill D, Huminiecki L, Iacono M, Ikeo K, Iwama A, Ishikawa T, Jakt M, Kanapin A, Katoh M, Kawasawa Y, Kelso J, Kitamura H, Kitano H, Kollias G, Krishnan SP, Kruger A, Kummerfeld SK, Kurochkin IV, Lareau LF, Lazarevic D, Lipovich L, Liu J, Liuni S, McWilliam S, Madan Babu M, Madera M, Marchionni L, Matsuda H, Matsuzawa S, Miki H, Mignone F, Miyake S, Morris K, Mottagui-Tabar S, Mulder N, Nakano N, Nakauchi H, Ng P, Nilsson R, Nishiguchi S, Nishikawa S, Nori F, Ohara O, Okazaki Y, Orlando V, Pang KC, Pavan WJ, Pavesi G, Pesole G, Petrovsky N, Piazza S, Reed J, Reid JF, Ring BZ, Ringwald M, Rost B, Ruan Y, Salzberg SL, Sandelin A, Schneider C, Schönbach C, Sekiguchi K, Semple CA, Seno S, Sessa L, Sheng Y, Shibata Y, Shimada H, Shimada K, Silva D, Sinclair B, Sperling S, Stupka E, Sugiura K, Sultana R, Takenaka Y, Taki K, Tammoja K, Tan SL, Tang S, Taylor MS, Tegner J, Teichmann SA, Ueda HR, van Nimwegen E, Verardo R, Wei CL, Yagi K, Yamanishi H, Zabarovsky E, Zhu S, Zimmer A, Hide W, Bult C, Grimmond SM, Teasdale RD, Liu ET, Brusic V, Quackenbush J, Wahlestedt C, Mattick JS, Hume DA, Kai C, Sasaki D, Tomaru Y, Fukuda S, Kanamori-Katayama M, Suzuki M, Aoki J, Arakawa T, Iida J, Imamura K, Itoh M, Kato T, Kawaji H, Kawagashira N, Kawashima T, Kojima M, Kondo S, Konno H, Nakano K, Ninomiya N, Nishio T, Okada M, Plessy C, Shibata K, Shiraki T, Suzuki S, Tagami M, Waki K, Watahiki A, Okamura-Oho Y, Suzuki H, Kawai J, Hayashizaki Y, FANTOM Consortium, RIKEN Genome Exploration Research Group and Genome Science Group (Genome Network Project Core Group) (2005) The transcriptional landscape of the mammalian genome. Science 309(5740):1559–1563PubMedCrossRef
99.
100.
Zurück zum Zitat Arita T, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Shoda K, Kawaguchi T, Hirajima S, Nagata H, Kubota T, Fujiwara H, Okamoto K, Otsuji E (2013) Circulating long non-coding RNAs in plasma of patients with gastric cancer. Anticancer Res 33(8):3185–3193PubMed Arita T, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Shoda K, Kawaguchi T, Hirajima S, Nagata H, Kubota T, Fujiwara H, Okamoto K, Otsuji E (2013) Circulating long non-coding RNAs in plasma of patients with gastric cancer. Anticancer Res 33(8):3185–3193PubMed
103.
Zurück zum Zitat Zhao Y, Guo Q, Chen J, Hu J, Wang S, Sun Y (2014) Role of long non-coding RNA HULC in cell proliferation, apoptosis and tumor metastasis of gastric cancer: a clinical and in vitro investigation. Oncol Rep 31(1):358–364PubMedCrossRef Zhao Y, Guo Q, Chen J, Hu J, Wang S, Sun Y (2014) Role of long non-coding RNA HULC in cell proliferation, apoptosis and tumor metastasis of gastric cancer: a clinical and in vitro investigation. Oncol Rep 31(1):358–364PubMedCrossRef
104.
Zurück zum Zitat Sun M, Xia R, Jin F, Xu T, Liu Z, De W, Liu X (2014) Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. Tumour Biol 35(2):1065–1073PubMedCrossRef Sun M, Xia R, Jin F, Xu T, Liu Z, De W, Liu X (2014) Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. Tumour Biol 35(2):1065–1073PubMedCrossRef
105.
Zurück zum Zitat Cao WJ, Wu HL, He BS, Zhang YS, Zhang ZY (2013) Analysis of long non-coding RNA expression profiles in gastric cancer. World J Gastroenterol 19(23):3658–3664PubMedPubMedCentralCrossRef Cao WJ, Wu HL, He BS, Zhang YS, Zhang ZY (2013) Analysis of long non-coding RNA expression profiles in gastric cancer. World J Gastroenterol 19(23):3658–3664PubMedPubMedCentralCrossRef
106.
Zurück zum Zitat Li CY, Liang GY, Yao WZ, Sui J, Shen X, Zhang YQ, Peng H, Hong WW, Ye YC, Zhang ZY, Zhang WH, Yin LH, Pu YP (2016) Integrated analysis of long non-coding RNA competing interactions reveals the potential role in progression of human gastric cancer. Int J Oncol 48(5):1965–1976PubMedCrossRef Li CY, Liang GY, Yao WZ, Sui J, Shen X, Zhang YQ, Peng H, Hong WW, Ye YC, Zhang ZY, Zhang WH, Yin LH, Pu YP (2016) Integrated analysis of long non-coding RNA competing interactions reveals the potential role in progression of human gastric cancer. Int J Oncol 48(5):1965–1976PubMedCrossRef
107.
Zurück zum Zitat Rich S, Ganz R, Levy PS (1983) Comparative actions of hydralazine, nifedipine and amrinone in primary pulmonary hypertension. Am J Cardiol 52(8):1104–1107PubMedCrossRef Rich S, Ganz R, Levy PS (1983) Comparative actions of hydralazine, nifedipine and amrinone in primary pulmonary hypertension. Am J Cardiol 52(8):1104–1107PubMedCrossRef
108.
Zurück zum Zitat Strolin Benedetti M, Rumigny JF, Dostert P (1984) Mechanisms of action and biochemical toxicology of valproic acid. Encéphale 10(4):177–188PubMed Strolin Benedetti M, Rumigny JF, Dostert P (1984) Mechanisms of action and biochemical toxicology of valproic acid. Encéphale 10(4):177–188PubMed
109.
Zurück zum Zitat Windle J, Prystowsky EN, Miles WM, Heger JJ (1987) Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide. Clin Pharmacol Ther 41(6):603–610PubMedCrossRef Windle J, Prystowsky EN, Miles WM, Heger JJ (1987) Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide. Clin Pharmacol Ther 41(6):603–610PubMedCrossRef
110.
Zurück zum Zitat Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM (2005) Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23(17):3948–3956PubMedCrossRef Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM (2005) Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23(17):3948–3956PubMedCrossRef
111.
Zurück zum Zitat Kaminskas Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL, Leighton JK, Patel H, Rahman A, Sridhara R, Wang YC, Pazdur R (2005) Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11(10):3604–3608PubMedCrossRef Kaminskas Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL, Leighton JK, Patel H, Rahman A, Sridhara R, Wang YC, Pazdur R (2005) Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11(10):3604–3608PubMedCrossRef
112.
Zurück zum Zitat Zambrano P, Segura-Pacheco B, Perez-Cardenas E, Cetina L, Revilla-Vazquez A, Taja-Chayeb L, Chavez-Blanco A, Angeles E, Cabrera G, Sandoval K, Trejo-Becerril C, Chanona-Vilchis J, Duenas-González A (2005) A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer 5:44PubMedPubMedCentralCrossRef Zambrano P, Segura-Pacheco B, Perez-Cardenas E, Cetina L, Revilla-Vazquez A, Taja-Chayeb L, Chavez-Blanco A, Angeles E, Cabrera G, Sandoval K, Trejo-Becerril C, Chanona-Vilchis J, Duenas-González A (2005) A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer 5:44PubMedPubMedCentralCrossRef
113.
Zurück zum Zitat Zhang X, Yashiro M, Ren J, Hirakawa K (2006) Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. Oncol Rep 16(3):563–568PubMed Zhang X, Yashiro M, Ren J, Hirakawa K (2006) Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. Oncol Rep 16(3):563–568PubMed
114.
Zurück zum Zitat Riester D, Hildmann C, Schwienhorst A (2007) Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases. Appl Microbio Biotechnol 75(3):499–514CrossRef Riester D, Hildmann C, Schwienhorst A (2007) Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases. Appl Microbio Biotechnol 75(3):499–514CrossRef
115.
Zurück zum Zitat Satoh A, Toyota M, Itoh F, Sasaki Y, Suzuki H, Ogi K, Kikuchi T, Mita H, Yamashita T, Kojima T, Kusano M, Fujita M, Hosokawa M, Endo T, Tokino T, Imai K (2003) Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 63(24):8606–8613PubMed Satoh A, Toyota M, Itoh F, Sasaki Y, Suzuki H, Ogi K, Kikuchi T, Mita H, Yamashita T, Kojima T, Kusano M, Fujita M, Hosokawa M, Endo T, Tokino T, Imai K (2003) Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 63(24):8606–8613PubMed
116.
Zurück zum Zitat Koga Y, Kitajima Y, Miyoshi A, Sato K, Sato S, Miyazaki K (2006) The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer. J Gastroenterol 41(2):133–139PubMedCrossRef Koga Y, Kitajima Y, Miyoshi A, Sato K, Sato S, Miyazaki K (2006) The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer. J Gastroenterol 41(2):133–139PubMedCrossRef
Metadaten
Titel
Epigenetic Mechanisms and Events in Gastric Cancer-Emerging Novel Biomarkers
verfasst von
Puneet
Hasan Raza Kazmi
Soni Kumari
Satendra Tiwari
A. Khanna
Gopeshwar Narayan
Publikationsdatum
19.03.2018
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 4/2018
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-018-0410-z

Weitere Artikel der Ausgabe 4/2018

Pathology & Oncology Research 4/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.